Hedge fund manager Kyle Bass’ has answered charges he is challenging pharmaceutical and biotech patents solely to make a profit with a big “so what.”
Attorneys for the man BigPharma has accused of exploiting the patent system, and more specifically the inter partes review (IPR) proceedings created by the America Invents Act to challenge issued patents, said in a brief filed earlier this week that “having an economic motive for petitioning the government simply does not turn the petition into an abuse of process.” Skiermont Puckett attorney Sarah Spires wrote in a brief opposing a request to sanction Bass’ Coalition for Affordable Drugs filed by patent owner Celgene Corp.: “At the heart of nearly every patent and nearly every IPR, the motivation is profit.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
